Bacterial-directed enzyme prodrug therapy

Journal of Controlled Release

Volumn 170, Issue 1, 2013, Pages 120-131

  Lehouritis, Panos ^a   Springer, Caroline ^b   Tangney, Mark ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Bacteria; BDEPT; Cancer; Gene therapy; Prodrug

Indexed keywords

BACTERIA; DISEASES; ENZYMES; GENES; TECHNOLOGY TRANSFER; TISSUE; TUMORS;

BDEPT; CANCER; CONVENTIONAL TREATMENTS; ENZYME COMBINATIONS; ENZYME-PRODRUG THERAPIES; OPTIMIZATION STRATEGY; PRODRUGS; TECHNICAL KNOW HOWS;

GENE THERAPY;

6 METHYLPURINE; 6 METHYLPURINE 2 DEOXYRIBOSIDE; 9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BACTERIAL VECTOR; BETA GLUCURONIDASE; CARBOXYPEPTIDASE G2; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUDARABINE; GANCICLOVIR; NITROREDUCTASE; ONCOLYTIC CLOSTRIDIA; ONCOLYTIC CLOSTRIDIUM BUTYRICUM; ONCOLYTIC CLOSTRIDIUM HISTOLYTICUM; ONCOLYTIC CLOSTRIDIUM NOVYI; ONCOLYTIC CLOSTRIDIUM SORDELLII; ONCOLYTIC CLOSTRIDIUM TETANI; ONCOLYTIC ESCHERICHIA COLI; ONCOLYTIC SALMONELLA; ONCOLYTIC SALMONELLA TYPHIMURIUM; PR 104; PRODRUG; PURINE NUCLEOSIDE PHOSPHORYLASE; TRETAZICAR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BACTERIAL DIRECTED ENZYME PRODRUG THERAPY; BACTERIAL GROWTH; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIOLYSIS; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER THERAPY; CLOSTRIDIA; CLOSTRIDIUM; CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM HISTOLYTICUM; CLOSTRIDIUM NOVYI; CLOSTRIDIUM SORDELLII; CLOSTRIDIUM TETANI; DRUG EFFICACY; ENZYME PRODRUG THERAPY; ESCHERICHIA COLI; GENE EXPRESSION; GENE TARGETING; GENE VECTOR; HOST CELL; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SALMONELLA; SALMONELLA TYPHIMURIUM; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

EID: 84878733457     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.05.005     Document Type: Review

References (151)

1. S.A. Hoption Cann, J.P. van Netten, C. van Netten, Dr William Coley and tumour regression: a place in history or in the future, Postgrad Med J 79 (2003) 672-680. (Pubitemid 38134682)
2. J.M. Pawelek, K.B. Low, D. Bermudes, Tumor-targeted Salmonella as a novel anticancer vector, Cancer Res. 57 (1997) 4537-4544. (Pubitemid 27441058)
3. L.M. Zheng, X. Luo, M. Feng, Z. Li, T. Le, M. Ittensohn, M. Trailsmith, D. Bermudes, S.L. Lin, I.C. King, Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector, Oncol. Res. 12 (2000) 127-135.
4. X. Luo, Z. Li, S. Lin, T. Le, M. Ittensohn, D. Bermudes, J.D. Runyab, S.Y. Shen, J. Chen, I.C. King, L.M. Zheng, Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models, Oncol. Res. 12 (2000) 501-508. (Pubitemid 33791811)
5. M. Sznol, S.L. Lin, D. Bermudes, L.M. Zheng, I. King, Use of preferentially replicating bacteria for the treatment of cancer, J. Clin. Invest. 105 (2000) 1027-1030. (Pubitemid 30217683)
6. P. Carmeliet, R.K. Jain, Angiogenesis in cancer and other diseases, Nature 407 (2000) 249-257.
7. J. Hamzah, M. Jugold, F. Kiessling, P. Rigby, M. Manzur, H.H. Marti, T. Rabie, S. Kaden, H.J. Grone, G.J. Hammerling, B. Arnold, R. Ganss, Vascular normalization in Rgs5-deficient tumours promotes immune destruction, Nature 453 (2008) 410-414. (Pubitemid 351693122)
8. S.K. Hobbs, W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin, R.K. Jain, Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment, Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 4607-4612. (Pubitemid 28207960)
9. M. Cronin, A.R. Akin, S.A. Collins, J. Meganck, J.B. Kim, C.K. Baban, S.A. Joyce, G.M. van Dam, N. Zhang, D. van Sinderen, G.C. O'Sullivan, N. Kasahara, C.G. Gahan, K.P. Francis, M. Tangney, High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting, PLoS One 7 (2012) e30940.
10. N.S. Forbes, L.L. Munn, D. Fukumura, R.K. Jain, Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors, Cancer Res. 63 (2003) 5188-5193. (Pubitemid 37139825)
11. S. Ganai, R.B. Arenas, J.P. Sauer, B. Bentley, N.S. Forbes, In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis, Cancer Gene Ther. 18 (2011) 457-466.
12. J.J. Min, H.J. Kim, J.H. Park, S. Moon, J.H. Jeong, Y.J. Hong, K.O. Cho, J.H. Nam, N. Kim, Y.K. Park, H.S. Bom, J.H. Rhee, H.E. Choy, Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli, Mol. Imag. Biol. 10 (2008) 54-61.
13. M. Cronin, D. Morrissey, S. Rajendran, S.M. El Mashad, D. van Sinderen, G.C. O'Sullivan, M. Tangney, Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors, Mol. Ther. 18 (2010) 1397-1407.
14. M.R. Benoit, D. Mayer, Y. Barak, I.Y. Chen, W. Hu, Z. Cheng, S.X. Wang, D.M. Spielman, S.S. Gambhir, A. Matin, Visualizing implanted tumors in mice with magnetic resonance imaging using magnetotactic bacteria, Clin. Cancer Res. 15 (2009) 5170-5177.
15. J. Stritzker, S. Weibel, P.J. Hill, T.A. Oelschlaeger, W. Goebel, A.A. Szalay, Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice, Int. J. Med. Microbiol. 297 (2007) 151-162. (Pubitemid 46678925)
16. Y.A. Yu, S. Shabahang, T.M. Timiryasova, Q. Zhang, R. Beltz, I. Gentschev,W. Goebel, A.A. Szalay, Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins, Nat. Biotechnol. 22 (2004) 313-320. (Pubitemid 38295764)
17. J.P. van Pijkeren, D. Morrissey, I.R. Monk, M. Cronin, S. Rajendran, G.C. O'Sullivan, C.G. Gahan, M. Tangney, A novel Listeria monocytogenes-based DNA delivery system for cancer gene therapy, Hum. Gene Ther. 21 (2010) 405-416.
18. M. Tangney, Gene therapy for cancer: dairy bacteria as delivery vectors, Discov. Med. 10 (2010) 195-200.
19. D. Morrissey, G.C. O'Sullivan, M. Tangney, Tumour targeting with systemically administered bacteria, Curr. Gene Ther. 10 (2010) 3-14.
20. R.K. Jain, L.T. Baxter, Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure, Cancer Res. 48 (1988) 7022-7032. (Pubitemid 19013976)
21. R.C. Parker, H.C. Plummer, C.O. Siebenmann, M.G. Chapman, Effect of histolyticus infection and toxin on transplantable mouse tumors, Proc. Soc. Exp. Biol. Med. 66 (1947) 461-467.
22. R.A. Malmgren, C.C. Flanigan, Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration, Cancer Res. 15 (1955) 473-478.
23. K. Engelbart, D. Gericke, Oncolysis by clostridia. V. Transplanted tumors of the hamster, Cancer Res. 24 (1964) 239-242.
24. H.J. Carey R, H. Whang, E. Neter, B. Bryant, Clostridial oncolysis in man, Eur. J. Cancer 3 (1967) 37-46.
25. D. Gericke, K. Engelbart, Oncolysis by clostridia. II. Experiments on a tumor spectrum with a variety of clostridia in combination with heavy metal, Cancer Res. 24 (1964) 217-221.
26. E.H. Thiele, R.N. Arison, G.E. Boxer, Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors, Cancer Res. 24 (1964) 222-233.
27. D. Gericke, F. Dietzel, W. Konig, I. Ruster, L. Schumacher, Further progress with oncolysis due to apathogenic clostridia, Zentralbl. Bakteriol. Orig. A 243 (1979) 102-112. (Pubitemid 9143851)
28. D. Gericke, F. Dietzel, I. Ruster, Further progresswith oncolysis due to local high frequency hyperthermia, local X-irradiation and apathogenic clostridia, J. Microw. Power 14 (1979) 163-166. (Pubitemid 10225187)
29. F. Dietzel, D. Gericke, Intensification of the oncolysis by clostridia by means of radio-frequency hyperthermy in experiments on animals - dependence on dosage and on intervals, (author's transl) Strahlenther. 153 (1977) 263-266. (Pubitemid 8097729)
30. J.R. Mose, Experiments to improve the oncolysis-effect of clostridial-strain M55, (author's transl) (Zentralbl. Bakteriol. Orig. A), 244 (1979) 541-545.
31. F. Dietzel, D. Gericke,W. Konig, Tumor hyperthermia using high frequency for increase of oncolysis by Clostridium butyricum (M 55), (Strahlenther.), 152 (1976) 537-541.
32. N.P. Minton, M.L. Mauchline, M.J. Lemmon, J.K. Brehm, M. Fox, N.P. Michael, A. Giaccia, J.M. Brown, Chemotherapeutic tumour targeting using clostridial spores, FEMS Microbiol. Rev. 17 (1995) 357-364.
33. M.E. Fox, M.J. Lemmon, M.L. Mauchline, T.O. Davis, A.J. Giaccia, N.P. Minton, J.M. Brown, Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia, Gene Ther. 3 (1996) 173-178. (Pubitemid 26117427)
34. M.J. Lemmon, P. van Zijl, M.E. Fox, M.L. Mauchline, A.J. Giaccia, N.P. Minton, J.M. Brown, Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment, Gene Ther. 4 (1997) 791-796. (Pubitemid 27380161)
35. P. Lambin, J. Theys, W. Landuyt, P. Rijken, A. van der Kogel, E. van der Schueren, R. Hodgkiss, J. Fowler, S. Nuyts, E. de Bruijn, L. Van Mellaert, J. Anne, Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours, Anaerobe 4 (1998) 183-188. (Pubitemid 28528803)
36. L.H. Dang, C. Bettegowda, D.L. Huso, K.W. Kinzler, B. Vogelstein, Combination bacteriolytic therapy for the treatment of experimental tumors, Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 15155-15160. (Pubitemid 34013985)
37. C. Bettegowda, L.H. Dang, R. Abrams, D.L. Huso, L. Dillehay, I. Cheong, N. Agrawal, S. Borzillary, J.M. McCaffery, E.L. Watson, K.S. Lin, F. Bunz, K. Baidoo, M.G. Pomper, K.W. Kinzler, B. Vogelstein, S. Zhou, Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15083-15088. (Pubitemid 37518020)
38. I. Cheong, S. Zhou, Tumor-specific liposomal drug releasemediated by liposomase, Methods Enzymol. 465 (2009) 251-265.
39. I. Cheong, X. Huang, C. Bettegowda, L.A. Diaz Jr., K.W. Kinzler, S. Zhou, B. Vogelstein, A bacterial protein enhances the release and efficacy of liposomal cancer drugs, Science 314 (2006) 1308-1311. (Pubitemid 44846406)
40. D. Bermudes, B. Low, J. Pawelek, Tumor-targeted Salmonella. Highly selective delivery vectors, Adv. Exp. Med. Biol. 465 (2000) 57-63. (Pubitemid 32193323)
41. K.B. Low, M. Ittensohn, X. Luo, L.M. Zheng, I. King, J.M. Pawelek, D. Bermudes, Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humans, Meth. Mol. Med. 90 (2004) 47-60.
42. K.B. Low, Construction of VNP20009, C. Springer (Ed.), Suicide gene ther. (2004) 47-59.
43. F.C. Neidhardt, Escherichia coli and Salmonella, American Society for microbiology, 1996.
44. K.B. Low, M. Ittensohn, T. Le, J. Platt, S. Sodi, M. Amoss, O. Ash, E. Carmichael, A. Chakraborty, J. Fischer, S.L. Lin, X. Luo, S.I. Miller, L. Zheng, I. King, J.M. Pawelek, D. Bermudes, Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo, Nat. Biotechnol. 17 (1999) 37-41. (Pubitemid 29037207)
45. K.C. Lee, L.M. Zheng, D. Margitich, B. Almassian, I. King, Evaluation of the acute and subchronic toxic effects in mice, rats, and monkeys of the genetically engineered and Escherichia coli cytosine deaminase gene-incorporated Salmonella strain, TAPET-CD, being developed as an antitumor agent, Int. J. Toxicol. 20 (2001) 207-217. (Pubitemid 32823772)
46. J.F. Toso, V.J. Gill, P. Hwu, F.M. Marincola, N.P. Restifo, D.J. Schwartzentruber, R.M. Sherry, S.L. Topalian, J.C. Yang, F. Stock, L.J. Freezer, K.E. Morton, C. Seipp, L. Haworth, S. Mavroukakis, D. White, S. MacDonald, J. Mao, M. Sznol, S.A. Rosenberg, Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma, J. Clin. Oncol. 20 (2002) 142-152. (Pubitemid 34032605)
47. C. Clairmont, K.C. Lee, J. Pike, M. Ittensohn, K.B. Low, J. Pawelek, D. Bermudes, S.M. Brecher, D. Margitich, J. Turnier, Z. Li, X. Luo, I. King, L.M. Zheng, Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium, J. Infect. Dis. 181 (2000) 1996-2002. (Pubitemid 30416163)
48. J.M. Pawelek, S. Sodi, A.K. Chakraborty, J.T. Platt, S. Miller, D.W. Holden, M. Hensel, K.B. Low, Salmonella pathogenicity island-2 and anticancer activity in mice, Cancer Gene Ther. 9 (2002) 813-818.
49. F. Avogadri, C. Martinoli, L. Petrovska, C. Chiodoni, P. Transidico, V. Bronte, R. Longhi, M.P. Colombo, G. Dougan, M. Rescigno, Cancer immunotherapy based on killing of Salmonella-infected tumor cells, Cancer Res. 65 (2005) 3920-3927. (Pubitemid 40616374)
50. K. Westphal, S. Leschner, J. Jablonska, H. Loessner, S. Weiss, Containment of tumor-colonizing bacteria by host neutrophils, Cancer Res. 68 (2008) 2952-2960. (Pubitemid 351556296)
51. Y.Barak, F. Schreiber, S.H. Thorne, C.H. Contag,D.Debeer, A.Matin, Role of nitricoxide in Salmonella typhimurium-mediated cancer cell killing, BMC Cancer 10 (2010) 146.
52. J. Platt, S. Sodi, M. Kelley, S. Rockwell, D. Bermudes, K.B. Low, J. Pawelek, Antitumour effects of genetically engineered Salmonella in combination with radiation, Eur. J. Cancer 36 (2000) 2397-2402.
53. C.K. Baban, M. Cronin, D. O'Hanlon, G.C. O'Sullivan, M. Tangney, Bacteria as vectors for gene therapy of cancer, Bioeng. Bugs 1 (2010) 385-394.
54. K.D. Bagshawe, Antibody directed enzymes revive anti-cancer prodrugs concept, Br. J. Cancer 56 (1987) 531-532. (Pubitemid 17165643)
55. K.D. Bagshawe, C.J. Springer, F. Searle, P. Antoniw, S.K. Sharma, R.G. Melton, R.F. Sherwood, A cytotoxic agent can be generated selectively at cancer sites, Br. J. Cancer 58 (1988) 700-703. (Pubitemid 19033380)
56. K.D. Bagshawe, Antibody-directed enzyme/prodrug therapy (ADEPT), Biochem. Soc. Trans. 18 (1990) 750-752. (Pubitemid 20359291)
57. L.F. Tietze, K. Schmuck, Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT, Curr. Pharm. Des. 17 (2011) 3527-3547.
58. R.J. Francis, S.K. Sharma, C. Springer, A.J. Green, L.D. Hope-Stone, L. Sena, J. Martin, K.L. Adamson, A. Robbins, L. Gumbrell, D. O'Malley, E. Tsiompanou, H. Shahbakhti, S. Webley, D. Hochhauser, A.J. Hilson, D. Blakey, R.H. Begent, A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours, Br. J. Cancer 87 (2002) 600-607.
59. A.N. Lukashev, C. Fuerer, M.J. Chen, P. Searle, R. Iggo, Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954, Hum. Gene Ther. 16 (2005) 1473-1483. (Pubitemid 41829022)
60. S. Schepelmann, C.J. Springer, Viral vectors for gene-directed enzyme prodrug therapy, Curr. Gene Ther. 6 (2006) 647-670. (Pubitemid 44890548)
61. M. Tychopoulos, L. Corcos, P. Genne, P. Beaune, I. deWaziers, A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPHcytochrome P450 reductase fusion protein, Cancer Gene Ther. 12 (2005) 497-508. (Pubitemid 40629340)
62. S. Schepelmann, L.M. Ogilvie, D. Hedley, F. Friedlos, J. Martin, I. Scanlon, P. Chen, R. Marais, C.J. Springer, Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2, Cancer Res. 67 (2007) 4949-4955. (Pubitemid 46910203)
63. P. Patel, J.G. Young, V. Mautner, D. Ashdown, S. Bonney, R.G. Pineda, S.I. Collins, P.F. Searle, D. Hull, E. Peers, J. Chester, D.M. Wallace, A. Doherty, H. Leung, L.S. Young, N.D. James, A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954, (correction of CB1984) Mol. Ther. 17 (2009) 1292-1299.
64. R. Satchi-Fainaro, H. Hailu, J.W. Davies, C. Summerford, R. Duncan, PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-β- lactamase and HPMA copolymer-C-Dox as a model combination, Bioconjug. Chem. 14 (2003) 797-804. (Pubitemid 36875440)
65. R.A. Spooner, F. Friedlos, K. Maycroft, S.M. Stribbling, J. Roussel, J. Brueggen, B. Stolz, T. O'Reilly, J. Wood, A. Matter, R. Marais, C.J. Springer, A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs, Br. J. Cancer 88 (2003) 1622-1630. (Pubitemid 36713792)
66. S. Knaggs, H. Malkin, H.M. Osborn, N.A.Williams, P. Yaqoob, New prodrugs derived from6-aminodopamine and 4-aminophenol as candidates for melanocyte-directed enzyme prodrug therapy (MDEPT), Org. Biomol. Chem. 3 (2005) 4002-4010. (Pubitemid 41640816)
67. L.F. Tietze, H.J. Schuster, K. Schmuck, I. Schuberth, F. Alves, Duocarmycin-based prodrugs for cancer prodrugmonotherapy, Bioorg.Med. Chem. 16 (2008) 6312-6318.
68. C.J. Springer, I. Niculescu-Duvaz, Prodrug-activating systems in suicide gene therapy, J. Clin. Invest. 105 (2000) 1161-1167. (Pubitemid 30266065)
69. I. Niculescu-Duvaz, R. Spooner, R. Marais, C.J. Springer, Gene-directed enzyme prodrug therapy, Bioconjug. Chem. 9 (1998) 4-22. (Pubitemid 28052081)
70. F.L. Moolten, Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy, Cancer Res. 46 (1986) 5276-5281. (Pubitemid 16008301)
71. L. Finzi, A. Kraemer, C. Capron, S. Noullet, D. Goere, C. Penna, B. Nordlinger, J. Legagneux, J.F. Emile, R. Malafosse, Improved retroviral suicide gene transfer in colon cancer cell lines after cell synchronization with methotrexate, J. Exp. Clin. Cancer Res. 30 (2011) 92.
72. D. Abate-Daga, N. Andreu, J. Camacho-Sanchez, R. Alemany, R. Herance, O. Millan, C. Fillat, Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing, PLoS One 6 (2011) e26142.
73. S. Suzuki, T. Tadakuma,M.Kunitomi, E. Takayama,M. Sato, T. Asano, H.Nakamura,M. Hayakawa, Liposome-mediated gene therapy using HSV-TK/ganciclovir under the control of human PSA promoter in prostate cancer cells, Urol. Int. 67 (2001) 216-223. (Pubitemid 34701821)
74. B.E. Huber, E.A. Austin, C.A. Richards, S.T. Davis, S.S. Good, Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase, Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8302-8306.
75. R. Marais, R.A. Spooner, S.M. Stribbling, Y. Light, J. Martin, C.J. Springer, A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy, Nat. Biotechnol. 15 (1997) 1373-1377. (Pubitemid 28022731)
76. M. Loeffler, G. Le'Negrate,M. Krajewska, J.C. Reed, Inhibition of tumor growth using Salmonella expressing Fas ligand, J. Natl Cancer Inst. 100 (2008) 1113-1116.
77. J.L. Royo, P.D. Becker, E.M. Camacho, A. Cebolla, C. Link, E. Santero, C.A. Guzman, In vivo gene regulation in Salmonella spp. by a salicylate-dependent control circuit, Nat. Meth. 4 (2007) 937-942. (Pubitemid 350042383)
78. H. Loessner, S. Leschner, A. Endmann, K. Westphal, K. Wolf, K. Kochruebe, T. Miloud, J. Altenbuchner, S. Weiss, Drug-inducible remote control of gene expression by probiotic Escherichia coli Nissle 1917 in intestine, tumor and gall bladder of mice, Microbes Infect. 11 (2009) 1097-1105.
79. Y. Hamaji, M. Fujimori, T. Sasaki, H. Matsuhashi, K. Matsui-Seki, Y. Shimatani-Shibata, Y. Kano, J. Amano, S. Taniguchi, Strong enhancement of recombinant cytosine deaminase activity in Bifidobacterium longum for tumor-targeting enzyme/ prodrug therapy, Biosci. Biotechnol. Biochem. 71 (2007) 874-883. (Pubitemid 46650927)
80. S.C. Liu, G.O. Ahn, M. Kioi, M.J. Dorie, A.V. Patterson, J.M. Brown, Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104, Cancer Res. 68 (2008) 7995-8003.
81. J.E. Galan, K. Nakayama, R. Curtiss 3rd, Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains, Gene 94 (1990) 29-35. (Pubitemid 20368266)
82. F. Friedlos, P. Lehouritis, L. Ogilvie, D. Hedley, L. Davies, D. Bermudes, I. King, J. Martin, R. Marais, C.J. Springer, Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy, Clin. Cancer Res. 14 (2008) 4259-4266.
83. W. Fu, H. Lan, S. Li, X. Han, T. Gao, D. Ren, Synergistic antitumor efficacy of suicide/ePNP gene and 6-methylpurine 2'-deoxyriboside via Salmonella against murine tumors, Cancer Gene Ther. 15 (2008) 474-484. (Pubitemid 351822189)
84. S. Ahmad, G. Casey, M. Cronin, S. Rajendran, P. Sweeney, M. Tangney, G.C. O'Sullivan, Induction of effective antitumor response after mucosal bacterial vector mediated DNA vaccination with endogenous prostate cancer specific antigen, J. Urol. 186 (2011) 687-693.
85. R. Singh, A. Wallecha, Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic, Hum. Vaccin. 7 (2011) 497-505.
86. Y. Paterson, P.D. Guirnalda, L.M. Wood, Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy, Semin. Immunol. 22 (2010) 183-189.
87. R.J. Knox, Roger G. Melton, Enzyme-prodrug Strategies for Cancer Therapy, 1999.
88. D. Niculescu-Duvaz, I. Niculescu-Duvaz, C.J. Springer, Design of prodrugs for suicide gene therapy, Meth. Mol. Med. 90 (2004) 161-202.
89. W.A. Denny, W.R. Wilson, The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies, J. Pharm. Pharmacol. 50 (1998) 387-394. (Pubitemid 28197416)
90. I. Niculescu-Duvaz, C.J. Springer, Introduction to the background, principles, and state of the art in suicide gene therapy, Mol. Biotechnol. 30 (2005) 71-88. (Pubitemid 41411170)
91. P.R. Race, A.L. Lovering, S.A. White, J.I. Grove, P.F. Searle, C.W. Wrighton, E.I. Hyde, Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954, J. Mol. Biol. 368 (2007) 481-492. (Pubitemid 46509477)
92. L.C. Davies, F. Friedlos, D. Hedley, J. Martin, L.M. Ogilvie, I.J. Scanlon, C.J. Springer, Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy, J. Med. Chem. 48 (2005) 5321-5328. (Pubitemid 41113917)
93. V. Capucha, E. Mendes, A.P. Francisco, M.J. Perry, Development of triazene prodrugs for ADEPT strategy: new insights into drug delivery system based on carboxypeptidase G2 activation, Bioorg. Med. Chem. Lett. 22 (22) (Nov 15 2012) 6903-6908.
94. R.J. Knox, F. Friedlos, R.F. Sherwood, R.G. Melton, G.M. Anlezark, The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) - II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase, Biochem. Pharmacol. 44 (1992) 2297-2301. (Pubitemid 23005634)
95. M.J. Lemmon, P. van Zijl, M.E. Fox, M.L. Mauchline, A.J. Giaccia, N.P. Minton, J.M. Brown, Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment, Gene. Ther. 4 (1997) 791-796. (Pubitemid 27380161)
96. J. Theys, O. Pennington, L. Dubois, G. Anlezark, T. Vaughan, A. Mengesha, W. Landuyt, J. Anne, P.J. Burke, P. Durre, B.G. Wouters, N.P. Minton, P. Lambin, Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo, Br. J. Cancer 95 (2006) 1212-1219. (Pubitemid 44658485)
97. S.H. Thorne, Y. Barak, W. Liang, M.H. Bachmann, J. Rao, C.H. Contag, A. Matin, CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy, Mol. Cancer Ther. 8 (2009) 333-341.
98. P.M. Swe, J.N. Copp, L.K. Green, C.P. Guise, A.M. Mowday, J.B. Smaill, A.V. Patterson, D.F. Ackerley, Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954, Biochem. Pharmacol. 84 (2012) 775-783.
99. M. Jaberipour, S.O. Vass, C.P. Guise, J.I. Grove, R.J. Knox, L. Hu, E.I. Hyde, P.F. Searle, Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations, Biochem. Pharmacol. 79 (2010) 102-111.
100. L. Hu, C. Yu, Y. Jiang, J. Han, Z. Li, P. Browne, P.R. Race, R.J. Knox, P.F. Searle, E.I. Hyde, Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy, J. Med. Chem. 46 (2003) 4818-4821. (Pubitemid 37352019)
101. S.O. Vass, D. Jarrom, W.R. Wilson, E.I. Hyde, P.F. Searle, E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954, Br. J. Cancer 100 (2009) 1903-1911.
102. C.J. Springer, P. Antoniw, K.D. Bagshawe, F. Searle, G.M. Bisset, M. Jarman, Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2, J. Med. Chem. 33 (1990) 677-681. (Pubitemid 20047592)
103. D. Niculescu-Duvaz, I. Niculescu-Duvaz, F. Friedlos, J. Martin, P. Lehouritis, R. Marais, C.J. Springer, Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT, J. Med. Chem. 46 (2003) 1690-1705. (Pubitemid 36444222)
104. C.M. Cheng, Y.L. Lu, K.H. Chuang, W.C. Hung, J. Shiea, Y.C. Su, C.H. Kao, B.M. Chen, S. Roffler, T.L. Cheng, Tumor-targeting prodrug-activating bacteria for cancer therapy, Cancer Gene Ther. 15 (2008) 393-401. (Pubitemid 351693224)
105. B.W. Hughes, A.H. Wells, Z. Bebok, V.K. Gadi, R.I. Garver Jr., W.B. Parker, E.J. Sorscher, Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene, Cancer Res. 55 (1995) 3339-3345.
106. G. Chen, B. Tang, B.Y. Yang, J.X. Chen, J.H. Zhou, J.H. Li, Z.C. Hua, Tumor-targeting Salmonella typhimurium, a natural tool for activation of prodrug 6MePdR and their combination therapy in murine melanoma model, Appl. Microbiol. Biotechnol. 97 (10) (May 2013) 4393-4401.
107. S.Nuyts, J. Theys,W. Landuyt, L. vanMellaert, P. Lambin, J. Anne, Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters, Anticancer. Res. 21 (2001) 857-861.
108. J. Theys, W. Landuyt, S. Nuyts, L. Van Mellaert, A. van Oosterom, P. Lambin, J. Anne, Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum, Cancer Gene Ther. 8 (2001) 294-297. (Pubitemid 32480066)
109. S.C. Liu, N.P. Minton, A.J. Giaccia, J.M. Brown, Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis, Gene Ther. 9 (2002) 291-296. (Pubitemid 34256904)
110. T. Nakamura, T. Sasaki, M. Fujimori, K. Yazawa, Y. Kano, J. Amano, S. Taniguchi, Cloned cytosine deaminase gene expression of Bifidobacteriumlongumand application to enzyme/pro-drug therapy of hypoxic solid tumors, Biosci. Biotechnol. Biochem. 66 (2002) 2362-2366. (Pubitemid 39251171)
111. S. Mei, J. Theys, W. Landuyt, J. Anne, P. Lambin, Optimization of tumor-targeted gene delivery by engineered attenuated Salmonella typhimurium, Anticancer. Res. 22 (2002) 3261-3266. (Pubitemid 36070101)
112. A. Hidaka, Y. Hamaji, T. Sasaki, S. Taniguchi, M. Fujimori, Exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy, Biosci. Biotechnol. Biochem. 71 (2007) 2921-2926.
113. T. Sasaki, M. Fujimori, Y. Hamaji, Y. Hama, K. Ito, J. Amano, S. Taniguchi, Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats, Cancer Sci. 97 (2006) 649-657. (Pubitemid 44056614)
114. C. Yi, Y. Huang, Z.Y. Guo, S.R. Wang, Antitumor effect of cytosine deaminase/ 5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma, Acta Pharmacol. Sin. 26 (2005) 629-634. (Pubitemid 40684466)
115. S.D. Mahan, G.C. Ireton, B.L. Stoddard, M.E. Black, Alanine-scanning mutagenesis reveals a cytosine deaminase mutant with altered substrate preference, Biochemistry 43 (2004) 8957-8964. (Pubitemid 38924430)
116. I. King, D. Bermudes, S. Lin, M. Belcourt, J. Pike, K. Troy, T. Le, M. Ittensohn, J. Mao, W. Lang, J.D. Runyan, X. Luo, Z. Li, L.M. Zheng, Tumor-targeted salmonella expressing cytosine deaminase as an anticancer agent, Hum. Gene Ther. 13 (2002) 1225-1233. (Pubitemid 34746702)
117. J. Nemunaitis, C. Cunningham, N. Senzer, J. Kuhn, J. Cramm, C. Litz, R. Cavagnolo, A. Cahill, C. Clairmont, M. Sznol, Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients, Cancer Gene Ther. 10 (2003) 737-744. (Pubitemid 37243794)
118. L. Dubois, T. Dresselaers, W. Landuyt, K. Paesmans, A. Mengesha, B.G. Wouters, P. Van Hecke, J. Theys, P. Lambin, Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression, Br. J. Cancer 96 (2007) 758-761. (Pubitemid 46376629)
119. S.C. Liu, N.P. Minton, A.J. Giaccia, J.M. Brown, Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. PG - 291-6, Gene Ther. 9 (2002) 291-296. (Pubitemid 34256904)
120. W. Tang, Y. He, S. Zhou, Y. Ma, G. Liu, A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer, J. Exp. Clin. Cancer Res. 28 (2009) 155.
121. S. Zeng, J. Zhang, Q. Liu, S. Wang, S. Wu, X. Peng, J. Shao, W. Huang, Suppression of murine melanoma growth by a vaccine of attenuated Salmonella carrying heat shock protein 70 and Herpes simplex virus-thymidine kinase genes, Oncol. Rep. 27 (2012) 798-806.
122. C. Grillot-Courvalin, S. Goussard, F. Huetz, D.M. Ojcius, P. Courvalin, Functional gene transfer from intracellular bacteria to mammalian cells, Nat. Biotechnol. 16 (1998) 862-866. (Pubitemid 28405858)
123. J. Stritzker, S. Pilgrim, A.A. Szalay, W. Goebel, Prodrug converting enzyme gene delivery by L. monocytogenes, BMC Cancer 8 (2008) 94.
124. J.A. Bridgewater, R.J. Knox, J.D. Pitts, M.K. Collins, C.J. Springer, The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite, Hum. Gene Ther. 8 (1997) 709-717. (Pubitemid 27202057)
125. R.A. Spooner, J. Martin, F. Friedlos, R. Marais, C.J. Springer, In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug, Cancer Gene Ther. 7 (2000) 1348-1356.
126. R.A. Spooner, K.A. Maycroft, H. Paterson, F. Friedlos, C.J. Springer, R. Marais, Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapy, Int. J. Cancer 93 (2001) 123-130. (Pubitemid 32539511)
127. J. Maurer, J. Jose, T.F. Meyer, Autodisplay: one-component system for efficient surface display and release of soluble recombinant proteins from Escherichia coli, J. Bacteriol. 179 (1997) 794-804. (Pubitemid 27051835)
128. V. Tafakori, G. Ahmadian, M.A. Amoozegar, Surface display of bacterial metallothioneins and a chitin binding domain on Escherichia coli increase cadmium adsorption and cell immobilization, Appl. Biochem. Biotechnol. 167 (2012) 462-473.
129. M. Sandkvist, M. Bagdasarian, Secretion of recombinant proteins by Gramnegative bacteria, Curr. Opin. Biotechnol. 7 (1996) 505-511. (Pubitemid 26381752)
130. K.J. Jeong, S.Y. Lee, Excretion of human beta-endorphin into culture medium by using outer membrane protein F as a fusion partner in recombinant Escherichia coli, Appl. Environ. Microbiol. 68 (2002) 4979-4985. (Pubitemid 35154808)
131. R.J. Francis, S.J. Mather, K. Chester, S.K. Sharma, J. Bhatia, R.B. Pedley, R. Waibel, A.J. Green, R.H. Begent, Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT), Eur. J. Nucl. Med. Mol. Imaging 31 (2004) 1090-1096. (Pubitemid 39050175)
132. R.J. Critchley, S. Jezzard, K.J. Radford, S. Goussard, N.R. Lemoine, C. Grillot- Courvalin, G. Vassaux, Potential therapeutic applications of recombinant, invasive E. coli, Gene Ther. 11 (2004) 1224-1233. (Pubitemid 39136786)
133. W. Fu, H. Lan, S. Liang, T. Gao, D. Ren, Suicide gene/prodrug therapy using salmonella-mediated delivery of Escherichia coli purine nucleoside phosphorylase gene and 6-methoxypurine 2'-deoxyriboside in murine mammary carcinoma 4T1 model, Cancer Sci. 99 (2008) 1172-1179. (Pubitemid 351676629)
134. S.M. Stribbling, F. Friedlos, J. Martin, L. Davies, R.A. Spooner, R. Marais, C.J. Springer, Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect, Hum. Gene Ther. 11 (2000) 285-292. (Pubitemid 30080386)
135. W.J. Liang, K.J. Wilson, H. Xie, J. Knol, S. Suzuki, N.G. Rutherford, P.J. Henderson, R.A. Jefferson, The gusBC genes of Escherichia coli encode a glucuronide transport system, J. Bacteriol. 187 (2005) 2377-2385. (Pubitemid 40389136)
136. N. Arrach, M. Zhao, S. Porwollik, R.M. Hoffman, M. McClelland, Salmonella promoters preferentially activated inside tumors, Cancer Res. 68 (2008) 4827-4832.
137. S.K. Sharma, K.D. Bagshawe, R.G. Melton, R.F. Sherwood, Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial, Cell Biophys. 21 (1992) 109-120.
138. D.C. Osipovitch, A.S. Parker, C.D. Makokha, J. Desrosiers, W.C. Kett, L. Moise, C. Bailey-Kellogg, K.E. Griswold, Design and analysis of immune-evading enzymes for ADEPT therapy, Protein Eng. Des. Sel.: PEDS 25 (2012) 613-624.
139. B.M. Chen, T.L. Cheng, S.C. Tzou, S.R. Roffler, Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy, Int. J. Cancer 94 (2001) 850-858. (Pubitemid 33032834)
140. M. Tangney, K.P. Francis, In vivo optical imaging in gene & cell therapy, Curr. Gene Ther. 12 (2012) 2-11.
141. M. Cronin, R.M. Stanton, K.P. Francis, M. Tangney, Bacterial vectors for imaging and cancer gene therapy: a review, Cancer Gene Ther. 19 (2012) 731-740.
142. S.A. Collins, K. Hiraoka, A. Inagaki, N. Kasahara, M. Tangney, PET imaging for gene & cell therapy, Curr. Gene Ther. 12 (2012) 20-32.
143. M. Tangney, Editorial: in vivo imaging& gene therapy, Curr. Gene Ther. 12 (2012) 1.
144. S. Bhaumik, T.V. Sekar, J. Depuy, J. Klimash, R. Paulmurugan, Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals, Gene Ther. 19 (2012) 295-302.
145. C.U. Riedel, I.R. Monk, P.G. Casey, D. Morrissey, G.C. O'Sullivan, M. Tangney, C. Hill, C.G. Gahan, Improved luciferase tagging system for Listeria monocytogenes allows real-time monitoring in vivo and in vitro, Appl. Environ. Microbiol. 73 (2007) 3091-3094. (Pubitemid 46718595)
146. S.A. Soghomonyan, M. Doubrovin, J. Pike, X. Luo, M. Ittensohn, J.D. Runyan, J. Balatoni, R. Finn, J.G. Tjuvajev, R. Blasberg, D. Bermudes, Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK, Cancer Gene Ther. 12 (2005) 101-108. (Pubitemid 39665248)
147. J. Tjuvajev, R. Blasberg, X. Luo, L.M. Zheng, I. King, D. Bermudes, Salmonellabased tumor-targeted cancer therapy: tumor amplified protein expression therapy (TAPET) for diagnostic imaging, J. Control. Release 74 (2001) 313-315. (Pubitemid 32727638)
148. P. Brader, J. Stritzker, C.C. Riedl, P. Zanzonico, S. Cai, E.M. Burnazi, E.R. Ghani, H. Hricak, A.A. Szalay, Y. Fong, R. Blasberg, Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging, Clin. Cancer Res. 14 (2008) 2295-2302. (Pubitemid 351551060)
149. T. Dresselaers, J. Theys, S. Nuyts, B. Wouters, E. de Bruijn, J. Anne, P. Lambin, P. Van Hecke, W. Landuyt, Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours, Br. J. Cancer 89 (2003) 1796-1801. (Pubitemid 37464156)
150. Y. Jamin, L. Smyth, S.P. Robinson, E.S. Poon, T.R. Eykyn, C.J. Springer, M.O. Leach, G.S. Payne, Noninvasive detection of carboxypeptidase G2 activity in vivo, NMR Biomed. 24 (2011) 343-350.
151. L.S. Borden Jr., P.E. Clark, M.C. Hall, Bladder cancer, Curr. Opin. Oncol. 16 (2004) 257-262. (Pubitemid 38543703)